SecBot SecBot

RLAY drug pipeline

Relay Therapeutics, Inc. · 2 rated drugs
$18.09
+0.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.3%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketThe Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.

zovegalisib Updated Nov 6

What to watch

The ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.

Bull case
  • Zovegalisib's mutant-selective allosteric mechanism is differentiated from approved PI3K-alpha inhibitors (alpelisib, inavolisib) and could offer better tolerability, especially less hyperglycemia, which has been a major limitation of the class.
  • Phase 1/2 ReDiscover data showed a 43% ORR and median 11.1-month PFS in heavily pre-treated patients, with FDA Breakthrough Therapy Designation validating the approach.
  • Massive institutional accumulation in Q2 2026: FMR LLC doubled to $376M, BlackRock $286M, State Street $189M, T. Rowe Price $144M, and new positions from Baker Bros., Westfield Capital, and Polar Capital.
Bear case
  • Zovegalisib is still unapproved and faces a long development timeline; Phase 3 ReDiscover-2 enrollment completes mid-2027, with pivotal data likely in 2028 or later.
  • Competition is entrenched: alpelisib (Novartis), inavolisib (Roche), and capivasertib (AstraZeneca) are already approved in the same or overlapping indications.
  • Insider selling is notable: CEO Sanjiv Patel sold $872K in October and $913K in September, and a 6M-share block was sold by SVF Pauling in August.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched by Elevar Therapeutics as of September 23, 2026.

LYRFIGTU lirafugratinib Updated Nov 6

What to watch

LYRFIGTU is already approved and commercialized by Elevar, so there is no upcoming binary catalyst for this specific drug. Watch for Relay's December 14, 2026 ASH presentation and regulatory update on zovegalisib in vascular anomalies (December 14, 2026) and Phase 3 ReDiscover-2 enrollment completion (estimated mid-2027) as the next major stock-moving events for Relay. Milestone/royalty payments from Elevar on LYRFIGTU sales could provide incremental upside but are not a hard catalyst.

Bull case
  • First FDA-approved molecule from Relay's Dynamo platform, validating its computational drug discovery approach.
  • 46% confirmed ORR with 11.8-month median duration of response in a difficult-to-treat cancer with about 8,000 annual U.S. diagnoses.
  • Up to $500M in potential milestone payments plus tiered royalties from Elevar, with $75M already received upfront.
Bear case
  • Relay licensed global commercialization rights to Elevar; Relay captures only milestones and royalties, not the full commercial value of the drug.
  • Cholangiocarcinoma is a relatively small market (~8,000 U.S. diagnoses/year), limiting peak sales potential.
  • Relay's Q3 2026 net loss was $81.7M with zero product revenue; the company remains pre-commercial on its own pipeline.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
May 5, 2026zovegalisibBreakthrough designation−1.3%−1.2%